Build status - In Progress

UPCC 05720: Enhance: A Randomized Double-blind Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-na ve Patients with Higher Risk Myelodysplastic Syndrome

Enrolling By Invitation
99 years or below
All
1 Location

Brief description of study

TBD

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 844323
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research